Quaternary Azetidines, Oxetanes, and Cyclobutanes via Allylic Allylation – Cope Rearrangement: Synthesis of linked heterocycles.

28 December 2025, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

Aliphatic 4-membered (hetero)cycles, such as cyclobutanes and azetidines, are becoming more prevalent as structural features on pharmaceutical leads and drugs. In particular, their rigidity and favorable physicochemical properties allow them to serve as bioisosteric replacements for common drug motifs. Substitution of (hetero)cyclobutanes in stereocontrolled fashion with pharmaceutically relevant functionality is still a modern challenge. Described herein is a method for constructing quaternary (hetero)cyclobutanes and linking them to other (hetero)cycles via an allylic alkylation/exocyclic strain-release Cope rearrangement. The one- or two- step sequence can yield uniquely linked heterocycles bearing an alkylidenemalononitrile functional group, which can be readily transformed into amides diastereoselectively. This study includes optimization and scope studies of the allyic alkylation/[3,3] sequence, enantioselective optimization using asymmetric allylic alkylation, and functional group interconversion studies to yield densely substituted drug-like scaffolds.

Keywords

alkylidenemalononitrile
asymmetric allylic alkylation
Cope rearrangement
azetidine
heterocycle

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Experimental procedures, characterization data (1H NMR, 19F NMR, 13C NMR, HRMS), and computational data.
Actions

Supplementary weblinks

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.